IUPAC/Chemical Name
N-(3-(6-(1-(2-(4-(2-(5-(4-(4-((2-Aminoethyl)amino)-2-(1-(4-chlorophenyl)cyclohexyl)quinazolin-7-yl)piperazin-1-yl)-5-oxopentanamido)ethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)-2-oxoethyl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-3-hydroxy-3-neopentylazetidine-1-carboxamide
InChi Key
LBIYUFWGBHNKTG-UHFFFAOYSA-N
InChi Code
InChI=1S/C68H86ClFN16O6/c1-45-52(33-49(70)34-54(45)79-64(90)85-41-66(91,42-85)40-65(2,3)4)60-53-36-55(77-62(53)75-44-74-60)46-37-76-86(38-46)39-59(89)83-24-19-67(20-25-83)43-81(31-32-92-67)26-23-72-57(87)9-8-10-58(88)84-29-27-82(28-30-84)50-15-16-51-56(35-50)78-63(80-61(51)73-22-21-71)68(17-6-5-7-18-68)47-11-13-48(69)14-12-47/h11-16,33-38,44,91H,5-10,17-32,39-43,71H2,1-4H3,(H,72,87)(H,79,90)(H,73,78,80)(H,74,75,77)
SMILES Code
O=C(N1CC(CC(C)(C)C)(O)C1)NC2=CC(F)=CC(C3=C4C(NC(C5=CN(CC(N(CC6)CCC76CN(CCNC(CCCC(N8CCN(C9=CC%10=NC(C%11(C%12=CC=C(Cl)C=C%12)CCCCC%11)=NC(NCCN)=C%10C=C9)CC8)=O)=O)CCO7)=O)N=C5)=C4)=NC=N3)=C2C
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
1,277.99
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1. Zhou Y, Kuang G, Li J, Halldin C, Nordberg A, Långström B, Tu Y, Ågren H. In silico studies of ASEM analogues targeting α7-nAChR and experimental verification. RSC Adv. 2021 Jan 21;11(7):3942-3951. doi: 10.1039/d0ra10435c. PMID: 35747361; PMCID: PMC9134020.
2. Teodoro R, Scheunemann M, Deuther-Conrad W, Wenzel B, Fasoli FM, Gotti C, Kranz M, Donat CK, Patt M, Hillmer A, Zheng MQ, Peters D, Steinbach J, Sabri O, Huang Y, Brust P. A Promising PET Tracer for Imaging of α₇ Nicotinic Acetylcholine Receptors in the Brain: Design, Synthesis, and in Vivo Evaluation of a Dibenzothiophene-Based Radioligand. Molecules. 2015 Oct 9;20(10):18387-421. doi: 10.3390/molecules201018387. PMID: 26473809; PMCID: PMC6332508.
3. Hillmer AT, Zheng MQ, Li S, Scheunemann M, Lin SF, Holden D, Labaree D, Ropchan J, Teodoro R, Deuther-Conrad W, Carson RE, Brust P, Huang Y. PET imaging evaluation of [(18)F]DBT-10, a novel radioligand specific to α7 nicotinic acetylcholine receptors, in nonhuman primates. Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):537-47. doi: 10.1007/s00259-015-3209-0. Epub 2015 Oct 12. PMID: 26455500; PMCID: PMC4733418.
